Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German an
Lilly’s main target is BPL-003, an intranasal formulation of mebufotenin benzoate, a synthetic form of the psychedelic compound 5-MeO-DMT. The candidate is being developed for treatment-resistant depression. In a Phase 2b study, a single dose produced statistically significant reductions in depressive symptoms, with most patients considered ready to leave the clinic after around 90 minutes.
heló, mi
az komoly
